Healthcare IT platform.
Immunemed has independently developed a new antibody treatment using the innate immune system and is expanding its application to hepatitis B, influenza, COVID-19, etc. For hepatitis B, it is in clinical trial phase 2 in Korea, and global clinical trial phase 2 for COVID-19 medication. Also, it is producing and selling kits to diagnose disease using the quick diagnosis method of lateral flow assay for infectious diseases such as Hantaan virus, leptospirosis, tsutsugamushi disease, dengue fever, dengue hemorrhagic fever, and typhoid.
Immunemed has independently developed a new antibody treatment using the innate immune system and is expanding its application to hepatitis B, influenza, COVID-19, etc. For hepatitis B, it is in clinical trial phase 2 in Korea, and global clinical trial phase 2 for COVID-19 medication. Also, it is producing and selling kits to diagnose disease using the quick diagnosis method of lateral flow assay for infectious diseases such as Hantaan virus, leptospirosis, tsutsugamushi disease, dengue fever, dengue hemorrhagic fever, and typhoid.
Investors 3
| Date | Name | Website |
| - | SV Investm... | svinvest.c... |
| - | Uno Invest... | unoi.co.kr |
| - | UTC Invest... | utc.co.kr |